394 related articles for article (PubMed ID: 25176644)
1. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.
Wang L; Xiong H; Wu F; Zhang Y; Wang J; Zhao L; Guo X; Chang LJ; Zhang Y; You MJ; Koochekpour S; Saleem M; Huang H; Lu J; Deng Y
Cell Rep; 2014 Sep; 8(5):1461-74. PubMed ID: 25176644
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer.
Martin PL; Yin JJ; Seng V; Casey O; Corey E; Morrissey C; Simpson RM; Kelly K
Oncogene; 2017 Jan; 36(4):525-533. PubMed ID: 27375016
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the Metabolic Consequences of PTEN Loss and Akt/Hexokinase 2 Hyperactivation in Prostate Cancer: A New Role for δ-Tocotrienol.
Fontana F; Anselmi M; Limonta P
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563663
[TBL] [Abstract][Full Text] [Related]
6. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
7. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
Misra UK; Pizzo SV
PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
[TBL] [Abstract][Full Text] [Related]
8. p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.
Cam M; Bid HK; Xiao L; Zambetti GP; Houghton PJ; Cam H
J Biol Chem; 2014 Feb; 289(7):4083-94. PubMed ID: 24366874
[TBL] [Abstract][Full Text] [Related]
9. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
Jung SH; Hwang HJ; Kang D; Park HA; Lee HC; Jeong D; Lee K; Park HJ; Ko YG; Lee JS
Oncogene; 2019 Mar; 38(10):1639-1650. PubMed ID: 30337688
[TBL] [Abstract][Full Text] [Related]
10. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
12. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
13.
Parisotto M; Grelet E; El Bizri R; Dai Y; Terzic J; Eckert D; Gargowitsch L; Bornert JM; Metzger D
J Exp Med; 2018 Jun; 215(6):1749-1763. PubMed ID: 29743291
[TBL] [Abstract][Full Text] [Related]
14. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
15. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB
Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130
[TBL] [Abstract][Full Text] [Related]
16. Zinc and p53 disrupt mitochondrial binding of HK2 by phosphorylating VDAC1.
Xue YN; Yu BB; Li JL; Guo R; Zhang LC; Sun LK; Liu YN; Li Y
Exp Cell Res; 2019 Jan; 374(1):249-258. PubMed ID: 30528266
[TBL] [Abstract][Full Text] [Related]
17. Targeting hexokinase 2 in castration-resistant prostate cancer.
Deng Y; Lu J
Mol Cell Oncol; 2015; 2(3):e974465. PubMed ID: 27308450
[TBL] [Abstract][Full Text] [Related]
18. The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.
Ding M; Van der Kwast TH; Vellanki RN; Foltz WD; McKee TD; Sonenberg N; Pandolfi PP; Koritzinsky M; Wouters BG
Mol Cancer Res; 2018 Apr; 16(4):682-695. PubMed ID: 29453322
[TBL] [Abstract][Full Text] [Related]
19. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
20. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.
Lee SL; Chou CC; Chuang HC; Hsu EC; Chiu PC; Kulp SK; Byrd JC; Chen CS
PLoS One; 2013; 8(6):e67149. PubMed ID: 23840605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
